



SmartPA Criteria Proposal

Drug/Drug Class:	Corticosteroids – Topical PDL Edit		
First Implementation Date:	June 21, 2012		
Proposed Date:	March 19, 2020		
Prepared For:	MO HealthNet		
Prepared By:	MO HealthNet/Conduent		
Criteria Status:	 □Existing Criteria ⊠Revision of Existing Criteria □New Criteria 		

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Topical corticosteroids are used for a variety of inflammatory skin conditions, including atopic dermatitis, seborrheic dermatitis, eczema, and plaque psoriasis.
 Pharmacotherapy choices for these conditions typically include emollients and topical corticosteroids. Emollients play an important role in the treatment of atopic dermatitis; however, topical steroids are the standard of care to which other treatments are compared. The selected potency should depend on the severity and location of disease. These agents control symptoms such as swelling, skin cracking, weeping, crusting, and scaling. This PDL class includes all potency classes and does not require additional criteria to gain access to or move from one group to another.

_		
Program-Specific	Preferred Agents	Non-Preferred Agents
Information:	Betamethasone Dip Lot	Ala-Scalp [®]
	 Betamethasone Val Crm/Lot/Oint 	Alclometasone
	Clobetasol Emollient Crm	Amcinonide
	Clobetasol Prop Crm/Gel/Oint/Soln	Apexicon E [®]
	Diflorasone Oint	• Beser [™]
	Fluticasone Prop Crm/Oint	Betamet Dip Aug Crm/Lot/Oint
	 Hydrocortisone Crm/Lot/Oint Rx 	Betamethasone AF Crm
	 Hydrocortisone Crm/Oint OTC 	Betamethasone Crm/Gel/Oint
	Mometasone Crm/Lot/Oint	Betamethasone Val Foam
	 Proctosol-HC[®] 	• Bryhali™
	Triamcinolone Crm/Oint/Lot	• Capex [®]
	(excluding gen Trianex [®])	Clobetasol Emulsion Foam
		Clobetasol Prop Foam/Lot/
		Shampoo/Spray
		Clobex [®]
		Clocortolone
		Clodan [®]
		Cloderm [®]
		Cordran [®]

Total program savings for the PDL classes will be regularly reviewed.

SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. ConduentTM and Conduent DesignTM are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

	•	Cutivate®
	•	Derma-Smoothe/FS®
	•	Dermatop [®]
	•	Desonate®
	•	Desonide
	•	Desowen [®]
	•	Desoximetasone
	•	Diflorasone Crm
	•	Diprolene®
	•	Elocon®
	•	Fluocinolone Crm/Oil/Oint/Soln
	•	Fluocinonide
	•	Fluocinonide Emollient
	•	Flurandrenolide
	•	Fluticasone Lot
	•	Halcinonide
	•	Halobetasol
	•	Halog®
	•	Hydrocortisone Absorbase Rx
	•	Hydrocortisone Buty Crm/Emol/Lot/
	•	Oint/Soln
	•	Hydrocortisone Lot OTC
	•	Hydrocortisone Val Crm/Oint
	•	Hydrocortisone/Aloe
	•	Impoyz™
	•	Kenalog [®] Aerosol
	•	Lexette™
	•	Locoid®
	•	Locoid [®] Lipocream
	•	Luxiq®
	•	Micort-HC [®]
	•	Nolix™
	•	Nucort™
	•	Olux®
	•	Olux-E®
	•	Pandel®
	•	Prednicarbate
	•	Psorcon [®]
	•	Scalpicin [®]
	•	Sernivo™
	•	Synalar®
	•	Temovate [®]
	•	Texacort™
	•	Topicort®
	•	Tovet™
	•	Triamcinolone 0.05% Oint (gen
		Trianex [®])
	•	Triamcinolone Acetonide Aerosol
	•	Trianex®
	•	Triderm™
	•	Tridesilon®
	•	Ultravate®
	_	

SmartPA PDL Proposal Form © 2020 Conduent Business Services, LLC. All rights reserved. Conduent[™] and Conduent Design[™] are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

		Ultravate [®] X Vanos [®] Vardeas [®]			
Type of Criteria:	 ☐ Increased risk of ADE ☐ Appropriate Indications 	Verdeso® Preferred Drug List Clinical Edit			
Data Sources:	□ Only Administrative Databases	☑ Databases + Prescriber-Supplied			
Setting & Popula	ation				
 Drug class for review: Corticosteroids – Topical Age range: All appropriate MO HealthNet participants 					
Approval Criteri	a				
 Failure to achieve desired therapeutic outcomes with trial on 4 or more preferred agents Documented trial period of preferred agents Documented ADE/ADR to preferred agents 					
Denial Criteria					
 Lack of adequate trial on required preferred agents Therapy will be denied if no approval criteria are met 					
Required Docun	nentation				
Laboratory Results: Progress Notes: Other:					
Disposition of Edit					
Denial: Exception Code "0160" (Preferred Drug List) Rule Type: PDL					
Default Approval Period					
1 year					
References					

- 1. Evidence-Based Medicine and Fiscal Analysis: "Topical Corticosteroids Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; January 2020.
- 2. Evidence-Based Medicine Analysis: "Topical Corticosteroids for Dermatological Disorders", UMKC-DIC; January 2020.
- 3. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2020.
- 4. USPDI, Micromedex; 2020.
- 5. Facts and Comparisons eAnswers (online); 2020 Clinical Drug Information, LLC.